<DOC>
	<DOCNO>NCT00101348</DOCNO>
	<brief_summary>This randomized phase I/II trial study side effect , best way give , best dose erlotinib bevacizumab give cetuximab well give erlotinib cetuximab together without bevacizumab work treat patient metastatic unresectable kidney , colorectal , head neck , pancreatic , non-small cell lung cancer . Erlotinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , cetuximab bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab bevacizumab may also stop growth tumor cell block blood flow tumor . Giving erlotinib together cetuximab and/or bevacizumab may kill tumor cell .</brief_summary>
	<brief_title>Erlotinib Cetuximab With Without Bevacizumab Treating Patients With Metastatic Unresectable Kidney , Colorectal , Head Neck , Pancreatic , Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) erlotinib combine cetuximab patient metastatic unresectable renal cell , colorectal , head neck , pancreatic , non-small cell lung cancer ( part 1 ) . II . Determine MTD bevacizumab combine cetuximab erlotinib patient ( part 2 ) . III . Determine toxic effect , quantitatively qualitatively , regimens patient . IV . Determine antitumor activity regimens , term tumor response , short-term survival , progression-free survival , patient . SECONDARY OBJECTIVES : I . Compare , preliminarily , toxicity antitumor activity profile regimens patient . OUTLINE : This open-label , multicenter , dose-escalation study erlotinib bevacizumab . Part 1 : Patients receive oral erlotinib daily day 1-28 . Patients also receive cetuximab IV 3 hour day 1 1 hour day 8 , 15 , 22 . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Part 2 : Patients receive erlotinib part 1 MTD cetuximab part 1 . Patients also receive bevacizumab IV 1½ hour day 1 1 hour day 15 . Cohorts 3-6 patient receive escalate dos bevacizumab MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . In group , course repeat every 28 day absence unacceptable toxicity disease progression . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Carcinoma , Mucoepidermoid</mesh_term>
	<mesh_term>Esthesioneuroblastoma , Olfactory</mesh_term>
	<mesh_term>Papilloma , Inverted</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>One follow histologically confirm diagnosis : Renal cell cancer Clear cell histology Metastatic unresectable disease AND meet 1 follow criterion : Recurrent disease Refractory interleukin2 ( IL2 ) interferonbased therapy Previously untreated AND candidate IL2based therapy Colorectal , head neck , pancreatic , nonsmall cell lung cancer Metastatic unresectable disease Progression prior standard treatment No evidence CNS disease , include follow ( part 2 ) : Primary brain tumor Brain metastases Paraffin embed tumor block available Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week Absolute neutrophil count ≥ 1,500 mm^3 Platelet count ≥ 100,000 mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) PTT INR ≤ 1.5 , unless receive fulldose warfarin ( part 2 ) Creatinine ≤ 1.5 time ULN Creatinine clearance ≥ 60 mL/min Calcium &lt; 10 mg/dL ( hypocalcemic agent allow ) No proteinuria* Protein &lt; 1 g 24hour urine collection* No unstable angina pectoris No cardiac arrhythmia No symptomatic congestive heart failure None follow allow part 2 : Myocardial infarction within past 6 month New York Heart Association class IIIV heart disease Serious cardiac arrhythmia require medication Peripheral vascular disease ≥ grade II Recent history cerebrovascular accident Uncontrolled hypertension ( blood pressure ≥ 150/85 mm Hg despite medication ) Other clinically significant cardiovascular disease No gastrointestinal ( GI ) tract disease result inability take oral medication No GI tract disease result requirement IV alimentation No active peptic ulcer disease No history allergic reaction attribute compound similar chemical biologic composition study drug No know hypersensitivity Chinese hamster ovary cell product recombinant human antibody ( part 2 ) No ongoing active infection No active infection require parenteral antibiotic ( part 2 ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study treatment No significant traumatic injury within past 28 day ( part 2 ) No history abnormality cornea ( e.g. , dry eye syndrome , Sjögren 's syndrome , congenital abnormality [ e.g. , Fuch 's dystrophy ] ) No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ breast cervix No psychiatric illness social situation would preclude study compliance No serious nonhealing wound ulcer bone fracture ( part 2 ) No uncontrolled illness See Disease Characteristics More 4 week since prior immunotherapy No prior cetuximab No prior bevacizumab Concurrent epoetin alfa darbepoetin alfa allow More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) More 4 week since prior radiotherapy No prior surgical procedure affect absorption Prior nephrectomy resection metastatic lesion allow provided patient fully recover More 7 day since prior core biopsy* More 28 day since prior major surgery open biopsy* No concurrent major surgery* Recovered prior therapy No prior erlotinib Concurrent bisphosphonates allow Concurrent fulldose anticoagulant allow provide follow criterion meet ( part 2 ) : Inrange INR ( usually 2 3 ) AND stable dose warfarin low molecular weight heparin No active bleeding No pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel varix ) No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>